Insulin-like growth factor-binding protein 2 (IGFBP-2) (IGFBP-2)

Insulin-like growth factor-binding protein 2 (IGFBP-2) is a multifunctional protein that plays a critical role in regulating the distribution and bioactivity of insulin-like growth factors (IGFs) throughout the body. It is characterized by its ability to bind IGF-I and IGF-II with high affinity, but it also exerts significant IGF-independent effects through its interaction with the extracellular matrix (ECM) and cell surface receptors. A key structural feature of IGFBP-2 is its heparin-binding domain 1 (HBD1), located in the central linker region, which facilitates binding to glycosaminoglycans like heparan sulfate. This interaction is essential for IGFBP-2-mediated cell migration, invasion, and attachment, particularly in the context of aggressive malignancies. In many cancers, including glioblastoma and prostate cancer, IGFBP-2 is highly overexpressed and serves as a driver of tumor progression and metastasis. Therapeutic strategies focusing on the functional modulation of the HBD1 domain aim to disrupt the protein's association with the cell surface, thereby neutralizing its pro-tumorigenic signaling. Beyond oncology, IGFBP-2 is involved in metabolic regulation and bone remodeling, making it a complex but promising target for drug development. Current research explores the use of monoclonal antibodies, antisense oligonucleotides, and small molecule inhibitors to modulate its activity in various disease states.

Other names

IBP2IGF-binding protein 2IGFBP2Insulin-like growth factor-binding protein 2 heparin-binding domain 1

Modulation of IGFBP-2 activity by blocking its heparin-binding domains to prevent interaction with the extracellular matrix and cell surface proteoglycans, thereby inhibiting IGF-independent signaling and reducing tumor cell invasion and survival.